This database contains 46 studies, archived under the term: "Sweden"
Click here to filter this large number of results.
Alzheimer’s disease (AD) and executive dysfunction. A case-control study on the significance of frontal white matter changes detected by diffusion tensor imaging (DTI)
Sjöbeck, Martin,
Elfgren, Christina,
Larsson, Elna-Marie,
Brockstedt, Sara,
Lätt, Jimmy,
Englund, Elisabet,
Passant, Ulla
White matter (WM) changes are frequently seen on structural imaging in AD but the clinical relevance of these changes is uncertain. Frontal WM pathology is often observed upon neuropathological examination in AD. Since frontal cortical/sub-cortical pathology is known to relate to executive dysfunction, the aim was to elucidate if frontal WM changes in AD correlated […]
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation
Schöll, Michael,
Almkvist, Ove,
Axelman, Karin,
Stefanova, Elka,
Wall, Anders,
Westman, Eric,
Långström, Bengt,
Lannfelt, Lars,
Graff, Caroline,
Nordberg, Agneta
Six young related pre-symptomatic carriers of a His163Tyr mutation in the presenilin 1 gene who will develop early onset familial Alzheimer’s disease (eoFAD), and a control group of 23 non-carriers underwent (18)F-fluorodeoxyglucose positron emission tomography (FDG PET). The mutation carriers were followed-up after 2 years. Multivariate analysis showed clear separation of carriers from non-carriers on […]
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]
The effect of midlife physical activity on structural brain changes in the elderly
Rovio, Suvi,
Spulber, Gabriela,
Nieminen, Lasse J.,
Niskanen, Eini,
Winblad, Bengt,
Tuomilehto, Jaakko,
Nissinen, Aulikki,
Soininen, Hilkka,
Kivipelto, Miia
Physical activity has been associated with decreased dementia risk in recent studies, but the effects for structural brain changes (i.e. white matter lesions (WML) and/or brain atrophy) have remained unclear. The CAIDE participants were a random population-based sample studied in midlife and re-examined on average 21 years later (n=2000). A subpopulation (n=75; 31 control, 23 […]
Physical activity and cognitive functioning in the oldest old: Within- and between-person cognitive activity and psychosocial mediators
Robitaille, Annie,
Muniz, Graciela,
Lindwall, Magnus,
Piccinin, Andrea M.,
Hoffman, Lesa,
Johansson, Boo,
Hofer, Scott M.
The current study examines the role of social contact intensity, cognitive activity, and depressive symptoms as within- and between-person mediators for the relationships between physical activity and cognitive functioning. All three types of mediators were considered simultaneously using multilevel structural equations modeling with longitudinal data. The sample consisted of 470 adults ranging from 79.37 to […]
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease
Lundin, Anders,
Dietrichs, Espen,
Haghighi, Sara,
Göller, Marie-Louise,
Heiberg, Arvid,
Loutfi, Ghada,
Widner, Håkan,
Wiktorin, Klas,
Wiklund, Leif,
Svenningsson, Anders,
Sonesson, Clas,
Waters, Nicholas,
Waters, Susanna,
Tedroff, Joakim
Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, […]
Effect of a high-intensity functional exercise program on functional balance: preplanned subgroup analyses of a randomized controlled trial in residential care facilities
Littbrand, Håkan,
Carlsson, Maine,
Lundin-Olsson, Lillemor,
Lindelöf, Nina,
Håglin, Lena,
Gustafson, Yngve,
Rosendahl, Erik
Objectives: To evaluate whether age, sex, depression, dementia disorder, nutritional status, or level of functional balance capacity influences the effect of a high-intensity functional weight-bearing exercise program on functional balance.; Design: Preplanned subgroup analyses of a randomized controlled trial.; Setting: Nine residential care facilities.; Participants: One hundred ninety-one people aged 65 to 100 dependent in […]
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment
Johansson, C.,
Ballard, C.,
Hansson, O.,
Palmqvist, S.,
Minthon, L.,
Aarsland, D.,
Londos, E.
Objective: This 30-week extension trial was a continuation of the first double-blind randomized controlled trial (RCT) to study memantine in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). The objective was to evaluate the presence of recurrence of symptoms upon drug withdrawal. Furthermore, the aim was to explore washout dynamics in order to […]